UK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMCShionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available Share XUK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMChttps://pharmaphorum.com/news/uks-nhs-to-fund-shionogis-mulpleo-after-backing-from-nice-and-smc/
NICE backs Ibrance for breast cancer via Cancer Drugs FundPfizer’s Ibrance has been approved for use by the NHS in England as a second-line treatment for advanced Share XNICE backs Ibrance for breast cancer via Cancer Drugs Fundhttps://pharmaphorum.com/news/nice-backs-ibrance-for-breast-cancer-via-cancer-drugs-fund/
NHS patients to get easier access to MS pill after NICE rethinkPatients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped Share XNHS patients to get easier access to MS pill after NICE rethinkhttps://pharmaphorum.com/news/nhs-patients-to-get-easier-access-to-ms-pill-after-nice-rethink/
NICE backs NHS funding for two cannabis-based drugs for first timeNICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant Share XNICE backs NHS funding for two cannabis-based drugs for first timehttps://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/
NICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBCNICE has said Roche’s Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a Share XNICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBChttps://pharmaphorum.com/news/nice-says-no-to-regular-nhs-funding-for-roches-tecentriq-in-tnbc/
NICE numbers at 20: trends in dealsNICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends Share XNICE numbers at 20: trends in dealshttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/
Blow to Novartis as NICE rejects migraine drug Aimovig againAfter NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with Share XBlow to Novartis as NICE rejects migraine drug Aimovig againhttps://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/
NICE numbers at 20 – a closer look at cancerThere has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Share XNICE numbers at 20 – a closer look at cancerhttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/
HAE patients get new option as NICE backs Takeda’s TakhzyroPatients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE Share XHAE patients get new option as NICE backs Takeda’s Takhzyrohttps://pharmaphorum.com/news/hae-patients-get-new-option-as-nice-backs-takedas-takhzyro/
